Furthermore, HIF-hydroxylase inhibitors, such as DMOG, are also known to activate the HIF2α pathway, which may potentially have therapeutic applications to recover IBD patients from anemia, via downregulation of hepatic hepcidin expression. This evidence concerns the gene HAMP and anemia (phenotype).